<DOC>
	<DOCNO>NCT02970552</DOCNO>
	<brief_summary>More 1.5 million HIV-infected woman become pregnant year . Approximately half access antiretroviral therapy ( ART ) , increase risk preterm birth ( PTB ) . Vaginal progesterone ( VP ) promise cost-effective intervention prevent PTB study high-risk population . This pilot study provide critical insight feasibility phase III trial determine whether woman willing participate , adhere study drug , complete follow-up .</brief_summary>
	<brief_title>Feasibility Vaginal Progesterone Reduce HIV-Associated Preterm Birth</brief_title>
	<detailed_description>This mixed method study evaluate feasibility acceptability trial VP prevent PTB among HIV-infected Zambian woman . To assess feasibility full-scale clinical trial , investigator implement pilot two-arm , double-masked , placebo-controlled trial VP among HIV-infected woman antenatal care Lusaka , Zambia . Participants randomly assign either daily self-administered VP indistinguishable placebo prior 24 week gestational age . In pilot study , investigator able estimate study uptake , adherence study product protocol , study retention . To assess acceptability trial test VP among HIV-infected woman Zambia , investigator employ qualitative approach longitudinal semi-structured interview among woman agree trial participation one-time semi-structured interview ( SSIs ) among decline participate .</detailed_description>
	<mesh_term>Premature Birth</mesh_term>
	<mesh_term>Progesterone</mesh_term>
	<criteria>1 . 18 year age old 2. viable intrauterine pregnancy confirm ultrasound 3. presentation antenatal care prior 24 week gestation 4. antibodyconfirmed HIV1 infection 5. initiate continue ART treatment pregnancy 6. ability willingness provide write informed consent 7. willing adhere study visit schedule 1. multiple gestation 2. nonresearch indication antenatal progesterone ( i.e . prior spontaneous PTB and/or cervical length &lt; 20mm screen ultrasound ) 3. plan situ cervical cerclage 4. evidence threaten abortion , preterm labor , rupture membrane 5. major fetal anomaly detect screen ultrasound 6. know uterine anomaly 7. know suspect allergy contraindication VP placebo component</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>PreTerm Birth</keyword>
	<keyword>HIV</keyword>
	<keyword>Vaginal Progesterone</keyword>
	<keyword>ART</keyword>
</DOC>